Author Archive: Jason Corum

Jason Corum

Jason is the director of web and new media with the Biotechnology Industry Organization (BIO). Prior to joining BIO in March 2011, he was the online communications manager for World Food Program USA and an online communications specialist with the Brookings Institution.

Jason is originally from Evergreen Park, Ill. and still thinks that Chicago is the best food city in the nation.  He spends his free time volunteering with the DC Books to Prisons Project, watching movies and reading comics.

Latest Posts

How to Survive the Patent Cliff: Eli Lilly’s CEO at the BIO CEO & Investor Conference

Fireside Chat

Like a number of companies, Eli Lilly is confronting a wave of patent expirations called the patent cliff. The company lost U.S. patent protection on the anti-psychotic Zyprexa in the fall of 2011 and they’re facing the losses of the antidepressant Cymbalta in December of 2013 and the osteoporosis drug Evista in 2014. The loss of protection endangers the company’s ability to profit from the drugs and they could face a $25 billion loss in Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: , , , , , , , ,

Celgene CEO on New Multiple Myeloma Drug Approvals

BIO CEO

Following on the heels of two big announcements in February, Celgene CEO Robert Hugin (one of FierceBiotech’s most influential people in biopharma) participated in a fireside chat with Joel Sendek, managing director and biotechnology analyst at Stifel Nicolaus & Company, at the 15th Annual BIO CEO & Investor Conference in New York. First, on Friday, February 8, the Food and Drug Administration (FDA) approved Celgene’s drug Pomalyst for patients with multiple myeloma whose disease has Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

The Presidential Inaugural: Looking Back at 30 Years of Biotech Policy Milestones

President Obama

As President Barack Obama prepares for his second inauguration, we decided that it would be a good time to take a look back on some of the most important pieces of legislation enacted by past presidential administrations and Congress with the support of the biotechnology industry. From helping create jobs, to propelling continued innovation and promoting research to find cures for rare diseases, the following pieces of legislation from the past 30 years are some Read More >

Public Policy  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

2012 Biotech Gift Guide

xmas-presents

Welcome to this year’s BIOtechNOW Gift Guide, our most loved biotech gift ideas from 2012 and beyond. Here you’ll find gifts that track your genetic history, interesting biotech books, and art! So whether you’re looking for a last-minute gift idea or a way to blow part of that holiday bonus consider this your guide to yuletide biotech bliss! Add your suggestions in the comments! 23andMe 23andMe is a DNA analysis service providing information and tools Read More >

Corporate  |  Leave a comment  |  Email This Post
Tags: , , , ,

FDASIA: A Step Forward for Patients

fdasia-panel

Earlier this year, Congress passed and President Obama signed the FDA Safety and Innovation Act (FDASIA) which included a re-authorization of the Prescription Drug User Fee Act (PDUFA). PDUFA provides essential funding to the FDA by authorizing the agency to charge user fees to companies seeking to have products reviewed. Originally enacted in 1992, it must be reauthorized every 5 years. Sara Radcliffe, executive vice president of health at BIO, moderated a panel of experts and advocates Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , , , , , ,